Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer (NCT06800313)
Phase 1/2 Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
🩺 Plain-English Summary (8th-Grade Level)
Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
Who can join: Review the eligibility criteria below.
Location: Rocky Mountain Cancer Center — Colorado Springs, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- Rocky Mountain Cancer Center — Colorado Springs, Colorado
- Sarah Cannon Research Institute 1 — Denver, Colorado
- Yale University — New Haven, Connecticut
- Florida Cancer Specialists — Sarasota, Florida
- XCancer Research Network LCMC Health EJGH — Metairie, Louisiana
- Dana Farber Mass General Brigham Cancer Care Inc — Boston, Massachusetts
- South Texas Accelerated Research Therapeutics, LLC (START) — Grand Rapids, Michigan
- Urology Cancer Center, PC — Omaha, Nebraska
- Memorial Sloan Kettering Cancer Center — Long Island City, New York
- Associated Medical Professionals — Syracuse, New York
- Duke University Medical Center — Durham, North Carolina
- Carolina Urologic Research Center — Myrtle Beach, South Carolina
- Sarah Cannon Research Institute — Nashville, Tennessee
- Urology Associates — Nashville, Tennessee
- NEXT Oncology — Austin, Texas
- MD Anderson Cancer Center — Houston, Texas
- Virginia Clinical Research — Norfolk, Virginia
- The Royal Marsden NHS Trust — Sutton,
📞 Contact the Study Coordinator
Phone: (844) 434-4210
Email: Participate-In-This-Study1@its.jnj.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Prostate Cancer
- Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC — Boston, Massachusetts
- PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer — Boston, Massachusetts
- Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer — Detroit, Michigan
- Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer — Basking Ridge, New Jersey
- Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers — New York, New York
- Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC — Tucson, Arizona
Explore by condition: All Metastatic Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.